Parkinson’s disease is the second most prevalent disease of the brain. It is characterized by midbrain dopaminergic neuronal degeneration accompanied by Lewy bodies, intra-cytoplasmic neuronal inclusions that consist mainly of alpha-synuclein. The cardinal motor features are muscular rigidity, bradykinesia, and resting tremor and, in advanced cases, postural instability. Symptoms are relieved by dopamine replacement therapy, but progress slowly. Clinical diagnosis is made according to medical history, neurological examinations and the response to anti-Parkinsonian drugs. There are no laboratory tests for diagnosis of the disease; however, for development of disease-modifying treatment, early diagnosis by objective laboratory test is required. Recently, postsynaptic sympathetic norepinephrine nerve terminals were found to be degenerated as well as mesencephalic dopaminergic neurons. Cardiac norepinephrine denervation can be seen by meta-iodine-benzyl guanidine scintigraphy, and may be a reliable diagnostic marker. Degeneration of norepinephrinergic and dopaminergic neurons suggests that catecholamines may play a central role in the neurodegeneration in Parkinson’s disease. Recently several studies showed that alpha-synuclein aggregates in cells exposed to dopamine. Here, we review findings relating to an early diagnostic marker for detecting degeneration of the peripheral sympathetic nerves, and propose the hypothesis that catecholamines cause alpha-synuclein to aggregate and play an important role in disease pathogenesis.
Halliday, G.; Lees, A.; Stern, M. Milestones in Parkinson’s disease—Clinical and pathologic features. Mov. Disord. 2011, 26, 1015–1021, doi:10.1002/mds.23669.
[3]
Forno, L.S. Neuropathology of Parkinson’s disease. J. Neuropathol. Exp. Neurol. 1996, 55, 259–272, doi:10.1097/00005072-199603000-00001.
[4]
De Rijk, M.C.; Tzourio, C.; Breteler, M.M.; Dartigues, J.F.; Amaducci, L.; Lopez-Pousa, S.; Manubens-Bertran, J.M.; Alperovitch, A.; Rocca, W.A. Prevalence of parkinsonism and Parkinson’s disease in Europe: the Europarkinson collaborative study. European Community concerted action on the epidemiology of Parkinson’s disease. J. Neurol. Neurosurg. Psychiat. 1997, 62, 10–15, doi:10.1136/jnnp.62.1.10.
[5]
Daniel, S.E.; Lees, A.J. Parkinson’s disease society brain bank, London: Overview and research. J. Neural Transm. 1993, 39, 165–172.
[6]
Chaudhuri, K.R.; Martinez-Martin, P. Quatitation of non-motor symptoms in Parkinson’s disease. E. J. Neurol. 2008, 15 (Suppl. 2), 2–8, doi:10.1111/j.1468-1331.2008.02212.x.
[7]
Tan, A.; Salqado, M.; Fahn, S. Rapid eye movement sleep behavior disorder preceding Parkinson’s disease with therapeutic response to levodopa. Mov. Disord. 1996, 11, 214–216, doi:10.1002/mds.870110216.
[8]
Ross, G.W.; Abbott, R.D.; Petrovitch, H.; Tanner, C.M.; White, L.R. Pre-motor features of Parkinson’s disease: tHe Honolulu-Asia aging study experience. Parkinsonism Relat. Disord. 2012, S1, S199–S202.
[9]
Savica, R.; Rocca, W.A.; Ahlskog, J.E. When does Parkinson disease start? Arch. Neurol. 2010, 67, 798–801, doi:10.1001/archneurol.2010.135.
[10]
Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 2004, 61, 561–566, doi:10.1001/archneur.61.4.561.
[11]
Olanow, C.W.; Rascol, O.; Hauser, R.; Feigin, P.D.; Jankovic, J.; Lang, A.; Langston, W.; Melamed, E.; Poewe, W.; Stocchi, F.; et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N. Engl. J. Med. 2009, 361, 1268–1278, doi:10.1056/NEJMoa0809335.
[12]
Ponsen, M.M.; Stoffers, D.; Booij, J.; van Eck-Smit, B.L.; Wolters, E.; Berendse, H.W. Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann. Neurol. 2004, 56, 173–181, doi:10.1002/ana.20160.
[13]
Ponsen, M.M.; Stoffers, D.; Twisk, J.W.; Wolters, E.; Berendse, H.W. Hyposmia and executive dysfunction as predictors of future Parkinson’s disease: A prospective study. Mov. Disord. 2009, 24, 1060–1065, doi:10.1002/mds.22534.
[14]
Sawada, H.; Oeda, T.; Yamamoto, K.; Kitagawa, N.; Mizuta, E.; Hosokawa, R.; Ohba, M.; Nishio, R.; Yamakawa, K.; Takeuchi, H.; et al. Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson disease. Eur. J. Neurol. 2009, 16, 174–182, doi:10.1111/j.1468-1331.2008.02372.x.
[15]
Sawada, H.; Yamakawa, K.; Yamakado, H.; Hosokawa, R.; Ohba, M.; Miyamoto, K.; Kawamura, T.; Shimohama, S. Cocaine and phenylephrine eye drop test for Parkinson disease. JAMA 2005, 293, 932–934.
[16]
Nagatsu, T.; Sawada, M. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson’s disease: Possible implications of glial cells. J. Neural Trasm. 2006, Suppl 71, 53–65.
Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: The TEMPO study. Arch. Neurol. 2002, 59, 1937–1943, doi:10.1001/archneur.59.12.1937.
[19]
Horimoto, Y.; Matsumoto, M.; Nakazawa, H.; Yuasa, H.; Morishita, M.; Akatsu, H.; Ikari, H.; Yamamoto, T.; Kosaka, K. Cognitive conditions of pathologically confirmed dementia with Lewy bodies and Parkinson’s disease with dementia. J. Neurol. Sci. 2003, 216, 105–108, doi:10.1016/S0022-510X(03)00220-X.
[20]
Koss, E.; Weiffenbach, J.M.; Haxby, J.V.; Friedland, R.P. Olfactory detection and identification performance are dissociated in early Alzheimer’s disease. Neurology 1988, 38, 1228–1232, doi:10.1212/WNL.38.8.1228.
[21]
Serby, M.; Larson, P.; Kallstein, D. The nature and course of olfactory deficits in Alzheimer’s disease. Am. J. Psychiat. 1991, 148, 357–360.
[22]
Doty, R.L.; Deems, D.A.; Stellar, S. Olfactory dysfunction in parkinsonism: A general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 1988, 38, 1237–1244, doi:10.1212/WNL.38.8.1237.
[23]
Müller, A.; Reichmann, H.; Livermore, A.; Hummel, T. Olfactory function in idiopathic Parkinson’s disease (IPD): Results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients. J. Neural Transm. 2002, 109, 805–811, doi:10.1007/s007020200067.
[24]
Braak, H.; Ghebremedhin, E.; Rub, U.; Bratzke, H.; Del Tredici, K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res. 2004, 318, 121–134, doi:10.1007/s00441-004-0956-9.
[25]
Haehner, A.; Hummel, T.; Reichman, H. Olfactory loss in Parkinson’s disease. Parkinson’s Dis. 2011, 2011, doi:10.4061/2011/450939.
Baba, T.; Kikuchi, A.; Hirayama, K.; Nishio, Y.; Hosokai, Y.; Kanno, S.; Hasegawa, T.; Sugeno, N.; Konno, M.; Suzuki, K.; et al. Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson’s disease: A 3 year longitudinal study. Brain 2012, 135, 161–169.
[28]
Olanow, C.W.; Perl, D.P.; DeMartino, G.N.; McNaught, K.S. Lewy-body formation is aggresome-related process: A hypothesis. Lancet Neurol. 2004, 3, 496–503.
[29]
Wakabayashi, K.; Tanji, K.; Mori, F.; Takahashi, H. The Lewy body in Parkinson’s disease: Molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 2007, 27, 494–506, doi:10.1111/j.1440-1789.2007.00803.x.
[30]
Iwanaga, K.; Wakabayashi, K.; Yoshimoto, M.; Tomita, I.; Satoh, H.; Takashima, H.; Satoh, A.; Seto, M.; Tsujihata, M.; Takahashi, H. Lewy body-type degeneration in cardiac plexus in Parkinson’s and incidental Lewy body diseases. Neurology 1999, 52, 1269–1271, doi:10.1212/WNL.52.6.1269.
[31]
Orimo, S.; Ozawa, E.; Oka, T.; Nakade, S.; Tsuchiya, K.; Yoshimoto, M.; Wakabayashi, K.; Takahashi, H. Different histopathology accounting for a decrease in myocardial MIBG uptake in PD and MSA. Neurology 2001, 57, 1140–1141, doi:10.1212/WNL.57.6.1140.
[32]
Orimo, S.; Takahashi, A.; Uchihara, T.; Mori, F.; Kakita, A.; Wakabayashi, K.; Takahashi, H. Degeneration of cardiac sympathetic nerve begins in the early disase process of Parkinson’s disease. Brain Pathol. 2007, 17, 24–30, doi:10.1111/j.1750-3639.2006.00032.x.
[33]
Golstein, D.S.; Holmes, C.; Li, S.T.; Bruce, S.; Metman, L.V.; Cannon, R.O., III. Cardiac sympathetic denervation in Parkinson’s disease. Ann. Intern. Med. 2000, 133, 338–347.
[34]
Braune, S.; Reinhardt, M.; Schnitzer, R.; Riedel, A.; Lücking, C.H. Cardiac uptake of [123I]MIBG separates Parkinson’s disease from multiple system atrophy. Neurology 1999, 53, 1020–1025, doi:10.1212/WNL.53.5.1020.
[35]
Druschky, A.; Hilz, M.J.; Platsch, G.; Radespiel-Tr？ger, M.; Druschky, K.; Kuwert, T.; Neund？rfer, B. Differentiation of Parkinson’s disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J. Neurol. Sci. 2000, 175, 3–12, doi:10.1016/S0022-510X(00)00279-3.
[36]
Takatsu, H.; Nagashima, K.; Murase, M.; Fujiwara, H.; Nishida, H.; Matsuo, H.; Watanabe, S.; Satomi, K. Differentiating Parkinson disease from multiple-system atrophy by measuring cardiac iodine-123 metaiodobenzylguanidine accumulation. JAMA 2000, 284, 44–45.
[37]
Kikuchi, A.; Baba, T.; Hasegawa, T.; Sugeno, N.; Konno, M.; Takeda, A. Differentiating Parkinson’s disease from multiple system atrophy by [123I] meta-iodobenzylguanidine myocardial scintigraphy and olfactory test. Parkinsonism Relat. Disord. 2011, 17, 698–700, doi:10.1016/j.parkreldis.2011.07.011.
[38]
Doty, R.L.; Bromley, S.M.; Stern, M.B. Olfactory testing as an aid in the diagnosis of Parkinson’s disease: Development of optimal discrimination criteria. Neurodegeneration 1995, 4, 93–97, doi:10.1006/neur.1995.0011.
[39]
Double, K.L.; Rowe, D.B.; Hayes, M.; Chan, D.K.; Blackie, J.; Corbett, A.; Joffe, R.; Fung, V.S.; Morris, J.; Halliday, G.M. Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test. Arch. Neurol. 2003, 60, 545–549, doi:10.1001/archneur.60.4.545.
[40]
Tipre, D.N.; Goldstein, D.S. Cardiac and extracardiac sympathetic denervation in Parkinson’s disease with orthostatic hypotension and in pure autonomic failure. J. Nucl. Med. 2005, 46, 1775–1781.
[41]
Matsui, H.; Udaka, F.; Oda, M.; Tamura, A.; Kubori, T.; Nishinaka, K.; Kameyama, M. Metaiodobenzylguanidine (MIBG) uptake in Parkinson’s disease also decreases at thyroid. Ann. Nucl. Med. 2005, 19, 225–229, doi:10.1007/BF02984609.
[42]
Nunomura, A.; Moreira, P.I.; Lee, H.G.; Zhu, X.; Castellani, R.J.; Smith, M.A.; Perry, G. Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases. CNS Neurol. Disord. Drug Targets 2007, 6, 411–423, doi:10.2174/187152707783399201.
[43]
Yamamoto, N.; Sawada, H.; Izumi, Y.; Kume, T.; Katsuki, H.; Shimohama, S.; Akaike, A. Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: Relevance to Parkinson disease. J. Biol. Chem. 2007, 282, 4364–4372.
[44]
Castellani, R.; Smith, M.A.; Richey, P.L.; Perry, G. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res. 1996, 737, 195–200, doi:10.1016/0006-8993(96)00729-9.
[45]
Sakka, N.; Sawada, H.; Izumi, Y.; Kume, T.; Katsuki, H.; Kaneko, S.; Shimohama, S.; Akaike, A. Dopamine is involved in selectivity of dopaminergic neuronal death by rotenone. Neuroreport 2003, 14, 2425–2428.
[46]
Bisaglia, M.; Tosatto, L.; Munari, F.; Tessari, I.; de Laureto, P.P.; Mammi, S.; Bubacco, L. Dopamine quinones interact with α-synuclein to form unstructured adducts. Biochem. Biophys. Res. Commun. 2010, 394, 424–428.
